Lineage Cell Therapeutics, Inc. Common Shares (no par value per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • May 1st, 2020 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Lineage Cell Therapeutics, Inc., a California corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
Lineage Cell Therapeutics, Inc. and ________, as Warrant Agent Form of Debt Securities Warrant Agreement Dated as of ______________Warrant Agreement • May 1st, 2020 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Debt Securities Warrant Agreement (this “Agreement”), dated as of ________ between Lineage Cell Therapeutics, Inc., a California corporation (the “Company”) and _________, a [corporation] [national banking association] organized and existing under the laws of _________ and having a corporate trust office in _______, as warrant agent (the “Warrant Agent”).
Lineage Cell Therapeutics, Inc. and ________, as Warrant Agent Form of Preferred Share Warrant Agreement Dated as of ___________Warrant Agreement • May 1st, 2020 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Preferred Share Warrant Agreement (this “Agreement”), dated as of between Lineage Cell Therapeutics, Inc., a California corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
